OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) Director David Pelizzon sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the transaction, the director directly owned 6,863,464 shares in the company, valued at $166,644,905.92. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
OrthoPediatrics Stock Performance
OrthoPediatrics stock traded down $0.47 during trading hours on Wednesday, reaching $24.03. 169,608 shares of the company were exchanged, compared to its average volume of 171,545. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average of $21.11 and a 200 day moving average of $18.53. The firm has a market cap of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. As a group, research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.
Institutional Trading of OrthoPediatrics
Analyst Ratings Changes
KIDS has been the subject of a number of recent analyst reports. Needham & Company LLC upped their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. BTIG Research increased their target price on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.44.
Check Out Our Latest Analysis on OrthoPediatrics
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Read More
- Five stocks we like better than OrthoPediatrics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
